U.S. Food and Drug Administration (FDA) · United States
FDA Cannabis Regulation - Foods and Dietary Supplements Prohibition
FDA's position is that CBD and THC cannot lawfully be added to foods or beverages or sold as dietary supplements in interstate commerce; hemp seed ingredients are allowed.
21 U.S.C. 321(ff)(3)(B), 331(ll), 343(r)(6)
What is FDA Cannabis Regulation - Foods and Dietary Supplements Prohibition?
FDA's position is that CBD and THC cannot lawfully be added to foods or beverages or sold as dietary supplements in interstate commerce; hemp seed ingredients are allowed. Apply to US food, beverage, edible and supplement marketing that contains or references CBD, THC, delta-8 or other cannabinoids.
FDA's position is that CBD and THC cannot lawfully be added to foods or beverages or sold as dietary supplements in interstate commerce; hemp seed ingredients are allowed.
How can marketing teams comply?
Apply to US food, beverage, edible and supplement marketing that contains or references CBD, THC, delta-8 or other cannabinoids.
What is FDA Cannabis Regulation - Foods and Dietary Supplements Prohibition?
FDA's position is that CBD and THC cannot lawfully be added to foods or beverages or sold as dietary supplements in interstate commerce; hemp seed ingredients are allowed.
Supplements, cosmetics, foods and CBD products become unapproved drugs if their marketing claims to diagnose, treat, cure, mitigate or prevent disease, and cosmetics also may not claim to affect body structure or function.
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
Food and supplement labels may link a substance to reduced disease risk only through FDA-authorized or qualified health claims, in the required form, and only on foods meeting nutrient eligibility; disease treatment claims are not allowed.
Infant formula and baby food marketing must not be misleading, including claims of equivalence to breast milk, disease prevention, guaranteed development or absolute contaminant-free status; formulas must meet FDA nutrient and notification requirements.
Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.
Prescription drug promotion must stay within the approved indication; information on unapproved uses may be shared only separately from promotion under FDA's safe-harbor guidance or in reply to unsolicited requests.
Request a free compliance scan of your homepage and book a time with Warrant.